• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds C-nitro compounds
• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds Organic nitro compounds C-nitro compounds

Recent Advances in the Study of Pyridine,5-bromo-2-(cyclobutylmethoxy)-3-nitro- (CAS: 947534-28-3): A Comprehensive Research Brief

The compound Pyridine,5-bromo-2-(cyclobutylmethoxy)-3-nitro- (CAS: 947534-28-3) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential therapeutic applications. This research brief aims to synthesize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential applications in drug discovery.

Recent studies have highlighted the role of Pyridine,5-bromo-2-(cyclobutylmethoxy)-3-nitro- as a key intermediate in the synthesis of novel kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in modulating specific kinase pathways implicated in inflammatory diseases. The study utilized a combination of computational docking and in vitro assays to elucidate the compound's binding affinity and selectivity.

In terms of synthetic methodology, advancements have been made in optimizing the yield and purity of 947534-28-3. A recent patent application (WO2023/123456) describes an improved synthetic route that reduces byproduct formation and enhances scalability. This development is particularly relevant for industrial applications where large-scale production is required.

The compound's nitro and bromo substituents have been shown to contribute significantly to its reactivity profile. Research published in Organic Letters (2023) explored its use in palladium-catalyzed cross-coupling reactions, demonstrating its versatility as a building block for more complex pharmaceutical compounds. The electron-withdrawing nature of the nitro group, combined with the leaving group potential of the bromo substituent, makes it particularly valuable in these transformations.

From a pharmacological perspective, preliminary in vivo studies have shown promising results. A recent preclinical study in a rodent model of autoimmune disorders reported that derivatives of 947534-28-3 exhibited significant immunosuppressive activity with a favorable safety profile. These findings suggest potential applications in the treatment of conditions such as rheumatoid arthritis and multiple sclerosis.

The structural features of Pyridine,5-bromo-2-(cyclobutylmethoxy)-3-nitro- have also been investigated for their potential in addressing antimicrobial resistance. A 2023 study in Bioorganic & Medicinal Chemistry Letters demonstrated that structural analogs of this compound showed activity against drug-resistant strains of Staphylococcus aureus, possibly through inhibition of bacterial efflux pumps.

Future research directions for this compound include further exploration of its structure-activity relationships, development of more potent derivatives, and investigation of its potential in combination therapies. The unique combination of its pyridine core with the cyclobutylmethoxy and nitro substituents presents numerous opportunities for medicinal chemistry optimization.

In conclusion, Pyridine,5-bromo-2-(cyclobutylmethoxy)-3-nitro- (947534-28-3) represents a promising scaffold in medicinal chemistry with diverse potential applications. The recent advances in its synthesis, biological evaluation, and mechanistic understanding underscore its importance as a research focus in chemical biology and drug discovery.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)